AR095196A1 - Medio de cultivo celular libre de suero - Google Patents
Medio de cultivo celular libre de sueroInfo
- Publication number
- AR095196A1 AR095196A1 ARP140100803A ARP140100803A AR095196A1 AR 095196 A1 AR095196 A1 AR 095196A1 AR P140100803 A ARP140100803 A AR P140100803A AR P140100803 A ARP140100803 A AR P140100803A AR 095196 A1 AR095196 A1 AR 095196A1
- Authority
- AR
- Argentina
- Prior art keywords
- serum free
- free cell
- cell cultivation
- cultivation media
- ornithine
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title abstract 2
- 238000004113 cell culture Methods 0.000 title 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 abstract 2
- 239000005700 Putrescine Substances 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 239000004017 serum-free culture medium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0043—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Abstract
La memoria descriptiva describe un medio de cultivo celular mejorado libre de suero animal, que puede usarse para la producción de una proteína de interés. La ornitina, o una combinación de ornitina y putrescina puede agregarse a medios libres de suero o medios definidos en forma química para mejorar la densidad de células viables, para reducir el tiempo de duplicación celular, y para aumentar la producción de una proteína de interés.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790136P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095196A1 true AR095196A1 (es) | 2015-09-30 |
Family
ID=51528781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100803A AR095196A1 (es) | 2013-03-15 | 2014-03-10 | Medio de cultivo celular libre de suero |
Country Status (22)
Country | Link |
---|---|
US (4) | US20140273095A1 (es) |
EP (4) | EP4159841A1 (es) |
JP (5) | JP6781039B2 (es) |
KR (5) | KR102278316B1 (es) |
CN (2) | CN113481148A (es) |
AR (1) | AR095196A1 (es) |
AU (4) | AU2014227804B2 (es) |
BR (2) | BR122020021864B1 (es) |
CA (3) | CA2906768C (es) |
DK (1) | DK2970876T3 (es) |
EA (3) | EA202190326A3 (es) |
ES (1) | ES2682929T3 (es) |
HK (1) | HK1213289A1 (es) |
HU (1) | HUE040233T2 (es) |
IL (5) | IL281515B1 (es) |
MX (3) | MX357977B (es) |
MY (1) | MY175957A (es) |
PL (1) | PL2970876T3 (es) |
PT (1) | PT2970876T (es) |
SG (3) | SG11201507072TA (es) |
TW (4) | TWI629359B (es) |
WO (1) | WO2014144198A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
WO2015148515A1 (en) * | 2014-03-24 | 2015-10-01 | Biogen Ma Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
TW202340452A (zh) * | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
EP3384004A1 (en) * | 2015-12-03 | 2018-10-10 | Merck Patent GmbH | Chemically defined media for the growth or detection of microorganisms |
KR20180047404A (ko) * | 2016-10-31 | 2018-05-10 | 삼성바이오에피스 주식회사 | 세포 배양 배지에서 원치 않는 배양 부산물을 감소시키는 공정 |
CN108220228A (zh) * | 2016-12-09 | 2018-06-29 | 上海迈泰君奥生物技术有限公司 | 无血清细胞培养基及高效表达重组蛋白质的方法 |
CN106635953B (zh) * | 2016-12-13 | 2021-02-19 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
US20190010531A1 (en) * | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
CN108103003B (zh) * | 2017-12-12 | 2021-03-05 | 四川百诺吉科技有限公司 | 一种适应pk-15全悬浮生长的无血清培养基及其制备方法和应用于pk-15细胞的全悬浮驯化方法 |
WO2019135238A1 (en) * | 2018-01-03 | 2019-07-11 | Technion Research & Development Foundation Limited | Naive pluripotent stem cell media |
US10961500B1 (en) * | 2019-04-23 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Cell culture medium for eukaryotic cells |
EP3969564A1 (en) * | 2019-05-16 | 2022-03-23 | Formycon AG | Method for reducing methionine oxidation in recombinant proteins |
CN110438066B (zh) * | 2019-08-19 | 2021-01-12 | 杭州百凌生物科技有限公司 | 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用 |
MY193349A (en) | 2019-12-06 | 2022-10-06 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
IL294765B2 (en) | 2020-01-21 | 2023-12-01 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
EP4281542A1 (en) | 2021-01-20 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
KR20220127465A (ko) | 2021-03-11 | 2022-09-20 | 주식회사 만도 | 조향 제어 장치 및 방법 |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072565A (en) | 1974-11-04 | 1978-02-07 | The Dow Chemical Company | Production of viruses in tissue culture without use of serum |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
EP0082974B1 (en) | 1981-12-24 | 1986-05-14 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for the cultivation of normal diploid cells and cultivation medium used therefor |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
FR2543158B1 (fr) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
DE3801236A1 (de) | 1988-01-18 | 1989-07-27 | Boehringer Mannheim Gmbh | Pentosansulfat-medium |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5529920A (en) | 1988-12-14 | 1996-06-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human liver epithelial cell line and culture media therefor |
JPH03504330A (ja) | 1988-12-14 | 1991-09-26 | アメリカ合衆国 | ヒト肝上皮細胞系のための細胞培地 |
DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5426699A (en) | 1993-10-25 | 1995-06-20 | Antec Corporation | Method and apparatus for digitizing a scrambled analog video signal |
EP0666312A1 (en) | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
WO1997004007A2 (de) | 1995-07-17 | 1997-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Metallhaltige ribonukleotidpolypeptide |
JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US6043092A (en) | 1996-03-18 | 2000-03-28 | University Of Pittsburgh | Cell culture media for mammalian cells |
US6146847A (en) | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
WO1999035495A2 (en) | 1998-01-12 | 1999-07-15 | Betagene, Inc. | Identification of substances that modify cellular secretory function |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
WO2000057891A1 (en) | 1999-03-30 | 2000-10-05 | Trustees Of Boston University | Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
US7070959B1 (en) * | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
CA2376379C (en) * | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
CN1114619C (zh) * | 1999-06-25 | 2003-07-16 | 中国科学院上海细胞生物学研究所 | 小鼠杂交瘤株Hepama-1分泌的肝癌鼠源单克隆抗体的制备方法 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
IL156910A0 (en) | 2001-01-16 | 2004-02-08 | Regeneron Pharma | Isolating cells expressing secreted proteins |
EP1321515A1 (en) * | 2001-12-21 | 2003-06-25 | Ingenium Pharmaceuticals AG | Method of culturing cells |
CN1180080C (zh) * | 2002-01-18 | 2004-12-15 | 中国科学院上海细胞生物学研究所 | 一种改进的肝癌鼠源单克隆抗体的制备方法 |
US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
EP1531666B1 (en) | 2002-05-29 | 2013-10-23 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
SI1623019T1 (sl) | 2003-05-15 | 2010-10-29 | Wyeth Llc | Omejeno glukozno dovajanje za živalsko celično kulturo |
US7303694B2 (en) | 2003-07-17 | 2007-12-04 | Wisconsin Alumni Research Foundation | Liquid crystals with reduced toxicity and applications thereof |
WO2005028626A2 (en) | 2003-09-18 | 2005-03-31 | Raven Biotechnologies, Inc. | Cell culture media |
EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
WO2006050050A2 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
US8273553B2 (en) | 2004-11-02 | 2012-09-25 | Ares Trading S.A. | Production of growth hormone in serum-free cell culture medium for mammalian cells |
AR058568A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
US20070212770A1 (en) * | 2006-01-04 | 2007-09-13 | Baxter International Inc. | Oligopeptide-free cell culture media |
EP1818392B1 (en) * | 2006-02-14 | 2010-08-25 | Genetix Limited | Cell culture medium |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
CN104152395B (zh) * | 2006-11-08 | 2020-03-10 | 惠氏公司 | 合理设计的细胞培养基 |
EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
MY147651A (en) | 2007-07-31 | 2012-12-31 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
CN100482786C (zh) * | 2007-12-28 | 2009-04-29 | 天津百若克医药生物技术有限责任公司 | 一种人胚肾293细胞扩增无蛋白培养基 |
US8637312B2 (en) | 2008-01-09 | 2014-01-28 | Cellca Gmbh | Mammalian culture media with polyamine and iron |
US20110229933A1 (en) * | 2008-09-26 | 2011-09-22 | SAchering Corporaton | High titer antibody production |
JP5719301B2 (ja) * | 2008-11-12 | 2015-05-13 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血清不含インスリン不含で第vii因子を産生する方法 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP3279326B1 (en) | 2009-06-02 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
CN101603026B (zh) | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
KR101574056B1 (ko) | 2009-07-31 | 2015-12-02 | 백스터 인터내셔널 인코포레이티드 | Adamts 단백질 발현을 위한 세포 배양 배지 |
US9045536B2 (en) * | 2009-12-23 | 2015-06-02 | Merck Sharp & Dohme Corp. | Cell line 3M |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
HUE037943T2 (hu) * | 2010-02-24 | 2018-09-28 | Chiesi Farm Spa | Eljárás rekombináns lizoszomális alfa-mannozidáz elõállítására és tisztítására |
CA2795461C (en) * | 2010-04-26 | 2018-04-24 | Novartis Ag | Improved cell cultivation process |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
DK2576580T3 (en) * | 2010-05-28 | 2016-10-17 | Hoffmann La Roche | LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE |
BR112013000512A2 (pt) * | 2010-07-08 | 2016-05-17 | Baxter Healthcare Sa | método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)' |
JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
AU2011296702A1 (en) | 2010-08-31 | 2013-03-21 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
JP5918246B2 (ja) | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤 |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
EP2660328A4 (en) * | 2010-12-28 | 2016-07-13 | Chugai Pharmaceutical Co Ltd | ANIMAL CELL CULTURE METHOD |
JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
BR112014017882A2 (pt) | 2012-01-23 | 2017-06-27 | Regeneron Pharma | formulações estabilizadas contendo anticorpos anti-ang-2 |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
JP6090735B2 (ja) | 2012-03-02 | 2017-03-08 | 国立大学法人山口大学 | 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法 |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013162057A1 (ja) | 2012-04-25 | 2013-10-31 | 独立行政法人理化学研究所 | 心筋指向性細胞を含む細胞製剤 |
JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
EP3103861B1 (en) | 2012-06-21 | 2020-09-30 | Baxalta GmbH | Virus filtration of cell culture media |
EA201590305A1 (ru) | 2012-08-02 | 2015-06-30 | Санофи | Изделие производства, включающее афлиберцепт или зив-афлиберцепт |
CA2881679C (en) | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
EP3747984A1 (en) * | 2012-10-23 | 2020-12-09 | Genzyme Corporation | Perfusion culturing methods and uses thereof |
JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
WO2014130872A2 (en) * | 2013-02-22 | 2014-08-28 | Genzyme Corporation | Microcarrier perfusion culturing methods and uses thereof |
EP3770263A1 (en) * | 2013-03-12 | 2021-01-27 | AGC Biologics, Inc. | Improved recombinant protein expression using a hybrid chef1 promoter |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
ES2743506T3 (es) * | 2013-03-14 | 2020-02-19 | Medimmune Llc | Producción de polipéptidos recombinantes |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CA2904377C (en) | 2013-03-15 | 2021-07-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
US20160237400A1 (en) | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
CN105324487B (zh) | 2013-05-29 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 唾液酸化的定量控制 |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
CN112481337A (zh) | 2014-01-13 | 2021-03-12 | 美国安进公司 | 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
US20170107553A1 (en) | 2014-06-03 | 2017-04-20 | Lupin Limited | Cell culture process for producing a protein |
AU2015317899A1 (en) | 2014-09-16 | 2017-04-06 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
SG11201705743YA (en) | 2015-04-01 | 2017-08-30 | Boehringer Ingelheim Int | Cell culture medium |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
KR101936049B1 (ko) | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
TW202140776A (zh) | 2016-04-26 | 2021-11-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
US20190010531A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
-
2014
- 2014-03-10 AR ARP140100803A patent/AR095196A1/es unknown
- 2014-03-13 TW TW103108931A patent/TWI629359B/zh active
- 2014-03-13 TW TW107120469A patent/TWI701333B/zh active
- 2014-03-13 TW TW111136096A patent/TW202325723A/zh unknown
- 2014-03-13 TW TW109124000A patent/TWI782295B/zh active
- 2014-03-14 SG SG11201507072TA patent/SG11201507072TA/en unknown
- 2014-03-14 IL IL281515A patent/IL281515B1/en unknown
- 2014-03-14 PL PL14723561T patent/PL2970876T3/pl unknown
- 2014-03-14 EA EA202190326A patent/EA202190326A3/ru unknown
- 2014-03-14 CA CA2906768A patent/CA2906768C/en active Active
- 2014-03-14 EP EP22209628.1A patent/EP4159841A1/en active Pending
- 2014-03-14 CA CA3188491A patent/CA3188491A1/en active Pending
- 2014-03-14 WO PCT/US2014/028501 patent/WO2014144198A1/en active Application Filing
- 2014-03-14 KR KR1020217007530A patent/KR102278316B1/ko active IP Right Grant
- 2014-03-14 MX MX2015013176A patent/MX357977B/es active IP Right Grant
- 2014-03-14 EA EA201591817A patent/EA037568B1/ru unknown
- 2014-03-14 CN CN202110770669.9A patent/CN113481148A/zh active Pending
- 2014-03-14 EP EP14723561.8A patent/EP2970876B1/en active Active
- 2014-03-14 EP EP18172141.6A patent/EP3378932A1/en active Pending
- 2014-03-14 CA CA3135232A patent/CA3135232A1/en active Pending
- 2014-03-14 JP JP2016502807A patent/JP6781039B2/ja active Active
- 2014-03-14 SG SG10202107444XA patent/SG10202107444XA/en unknown
- 2014-03-14 KR KR1020157027270A patent/KR102166166B1/ko active IP Right Grant
- 2014-03-14 KR KR1020207028935A patent/KR102229380B1/ko active IP Right Grant
- 2014-03-14 ES ES14723561.8T patent/ES2682929T3/es active Active
- 2014-03-14 EA EA202191602A patent/EA202191602A3/ru unknown
- 2014-03-14 EP EP21184357.8A patent/EP3919611A1/en active Pending
- 2014-03-14 IL IL300911A patent/IL300911A/en unknown
- 2014-03-14 CN CN201480023485.4A patent/CN105143444A/zh active Pending
- 2014-03-14 BR BR122020021864-9A patent/BR122020021864B1/pt active IP Right Grant
- 2014-03-14 BR BR112015022682-5A patent/BR112015022682B1/pt active IP Right Grant
- 2014-03-14 HU HUE14723561A patent/HUE040233T2/hu unknown
- 2014-03-14 SG SG10201707153UA patent/SG10201707153UA/en unknown
- 2014-03-14 PT PT14723561T patent/PT2970876T/pt unknown
- 2014-03-14 KR KR1020217021749A patent/KR20210090732A/ko not_active IP Right Cessation
- 2014-03-14 DK DK14723561.8T patent/DK2970876T3/en active
- 2014-03-14 US US14/211,245 patent/US20140273095A1/en not_active Abandoned
- 2014-03-14 AU AU2014227804A patent/AU2014227804B2/en active Active
- 2014-03-14 KR KR1020227027409A patent/KR20220116571A/ko not_active Application Discontinuation
- 2014-03-14 MY MYPI2015702985A patent/MY175957A/en unknown
-
2015
- 2015-09-06 IL IL241195A patent/IL241195B/en active IP Right Grant
- 2015-09-15 MX MX2021001859A patent/MX2021001859A/es unknown
- 2015-09-15 MX MX2021008627A patent/MX2021008627A/es unknown
-
2016
- 2016-01-29 HK HK16101075.8A patent/HK1213289A1/zh unknown
-
2019
- 2019-01-28 IL IL264499A patent/IL264499A/en unknown
- 2019-04-25 JP JP2019083625A patent/JP6944969B2/ja active Active
-
2020
- 2020-01-03 AU AU2020200052A patent/AU2020200052B2/en active Active
- 2020-01-14 US US16/742,695 patent/US11332771B2/en active Active
-
2021
- 2021-07-15 AU AU2021205088A patent/AU2021205088B2/en active Active
- 2021-08-16 JP JP2021132239A patent/JP2021180682A/ja not_active Withdrawn
-
2022
- 2022-01-10 IL IL289724A patent/IL289724B2/en unknown
- 2022-04-04 US US17/712,697 patent/US20220228187A1/en active Pending
- 2022-08-04 AU AU2022211862A patent/AU2022211862A1/en active Pending
- 2022-08-05 US US17/882,224 patent/US20220372436A1/en active Pending
- 2022-09-14 JP JP2022145754A patent/JP7429743B2/ja active Active
-
2023
- 2023-11-06 JP JP2023189068A patent/JP2024001357A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095196A1 (es) | Medio de cultivo celular libre de suero | |
CY1119098T1 (el) | Αγωνιστες fgfr1 και μεθοδοι χρησης | |
CR20180525A (es) | Producción de ácido ribonucleico libre de células | |
AR105602A1 (es) | Medio de cultivo celular suplementado con taurina y métodos de utilización | |
TR201904270T4 (tr) | Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller. | |
BR112015031637A2 (pt) | conjuntos de mistura incluindo impelidores magnéticos | |
CY1118885T1 (el) | Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης | |
UY34885A (es) | Proteínas de unión anti-mesotelina | |
UY4211Q (es) | Pizarra para marcadores | |
CR20150658A (es) | Montajes de mezcla que incluyen impulsores magnéticos | |
BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
CL2010000691A1 (es) | Sistemas, dispositivos y/o metodos para gestionar cojinetes magneticos. | |
UY4230Q (es) | Bocadillo retorcido para mascota | |
CY1118893T1 (el) | Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα | |
UY34167A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
AR095048A1 (es) | Proceso electroquímico para el acoplamiento de fenol a anilina | |
CL2017002427A1 (es) | Producción de ácido ribonucleico libre de células. | |
UY34335A (es) | ?dispositivos, sistemas, y métodos para procesar materiales heterogéneos?. | |
RS54073B1 (en) | STROMAL MATERIAL CELLS | |
UY34371A (es) | Moléculas de ácido nucleico que se dirigen a rps6 y confieren resistencia a plagas de coleópteros. | |
AR081151A1 (es) | Metodo para producir bacterias pertenecientes al genero bifidobacterium | |
RU2011135537A (ru) | Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов | |
AR086030A1 (es) | Metodos y dispositivos para amplificar acidos nucleicos | |
EA201391344A1 (ru) | Способ увеличения расхода водной дисперсии |